• Muhammad Aaqib Shamim, Subhanwita Manna, Pradeep Dwivedi, Mukesh Kumar Swami, Swapnajeet Sahoo, Ravindra Shukla, Shival Srivastav, Kashish Thaper, Aswini Saravanan, Abhishek Anil, Shoban Babu Varthya, Surjit Singh, Muhammad Aasim Shamim, Prakisini Satapathy, Soosanna Kumary Chattu, Vijay Kumar Chattu, Bijaya K Padhi, and Ranjit Sah.
• Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India.
• Medicine (Baltimore). 2023 Nov 10; 102 (45): e35937e35937.

BackgroundMajor depressive disorder is often resistant to first-line treatment, with around 30% failing to respond to traditional therapy. Treatment-resistant depression results in prolonged hospitalization and healthcare costs. Anti-inflammatory drugs have shown promising results in depression not responding to initial therapy. Minocycline has anti-inflammatory properties and crosses the blood-brain barrier. It has demonstrated varied results in several randomized controlled trials (RCTs).MethodsWe assessed the efficacy of minocycline compared to placebo in depression not responding to one first-line antidepressant via a systematic review and meta-analysis. We performed a comprehensive literature search across PubMed, Cochrane, and Scopus for RCTs. We visualized the results using forest plots and drapery plots. We assessed and explored heterogeneity using I2, prediction interval, and meta-regression. Then, we rated the certainty of the evidence.ResultsFour RCTs revealed a non-significant difference in depression severity [-3.93; 95% CI: -16.14 to 8.28], rate of response [1.15; 0.33-4.01], and rate of remission [0.94; 0.44-2.01]. However, the reduction in depression severity is significant at a trend of P < .1. The high between-study heterogeneity (I2 = 78%) for depression severity could be answered by meta-regression (P = .02) for the duration of therapy.ConclusionThere is no significant difference with minocycline compared to placebo for depression not responding to first-line antidepressant therapy. However, the treatment response varies with treatment duration and patients' neuroinflammatory state. Thus, larger and longer RCTs, especially in diverse disease subgroups, are needed for further insight. This is needed to allow greater precision medicine in depression and avoid elevated healthcare expenditure associated with hit-and-trial regimens.RegistrationCRD42023398476 (PROSPERO).Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

27 keywords...

hide…